Alpha Tau Medical
DRTS
14.25
-0.23
-1.59%
Alpha Tau Medical
US · DRTS
#3046 by market cap
Listed 1970
14.25
-0.23
-1.59%
Live - 5344 symbols - heartbeat 389s ago
· 2026-10-08 07:24
Pre-market
14.25
0.00%
After-hours
14.25
0.00%
- Market cap
- 1.32B
- P/E (TTM)i
- -13.70
- P/Bi
- 29.87
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on DRTS?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Key ratios & quality
- Enterprise valuei
- 1.25B
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.37M | 1.70M | 2.34M | 11.25M | 9.26M | 9.02M | 10.22M |
| Research & development | 6.64M | 7.54M | 11.45M | 20.89M | 26.42M | 27.02M | 32.07M |
| Operating profit | -8.01M | -9.24M | -13.79M | -32.14M | -35.68M | -36.04M | -42.29M |
| Pretax profit | -8.32M | -8.72M | -27.26M | -33.74M | -29.14M | -31.74M | -42.51M |
| Tax | 146.00K | 158.00K | 7.00K | 20.00K | 16.00K | 6.00K | 121.00K |
| Net profit | -8.46M | -8.88M | -27.27M | -33.76M | -29.16M | -31.75M | -42.63M |
| Basic EPS | 0 | 0 | 0 | -1 | 0 | 0 | -1 |
| Diluted EPS | -0.12 | -0.13 | -0.40 | -0.53 | -0.42 | -0.45 | -0.53 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 2.14M | 2.64M | 2.42M | 3.03M | 2.34M | 3.88M |
| Research & development | 7.17M | 7.01M | 8.31M | 9.58M | 10.98M | 9.91M |
| Operating profit | -9.31M | -9.65M | -10.73M | -12.60M | -13.31M | -13.78M |
| Pretax profit | -8.59M | -10.05M | -11.69M | -12.17M | -22.95M | -45.58M |
| Tax | 99.00K | 65.00K | -8.00K | -35.00K | -11.00K | 229.00K |
| Net profit | -8.69M | -10.11M | -11.69M | -12.14M | -22.94M | -45.81M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | -1 |
| Diluted EPS | -0.12 | -0.13 | -0.14 | -0.14 | -0.26 | -0.50 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 29.83M | 47.46M | 32.64M | 106.48M | 85.76M | 64.23M | 78.30M |
| Cash & ST investments | 28.13M | 46.02M | 31.32M | 104.53M | 81.79M | 59.60M | 73.13M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 31.56M | 52.99M | 42.22M | 120.15M | 107.39M | 86.20M | 105.65M |
| Total current liabilities | 1.35M | 2.09M | 4.41M | 4.34M | 7.10M | 8.68M | 10.51M |
| Short-term debt | -- | -- | -- | 669.00K | 1.06M | 1.01M | 1.13M |
| Long-term debt | -- | -- | -- | -- | 5.61M | 5.56M | 6.35M |
| Total liabilities | 31,750,000.00 | 61,418,000.00 | 76,992,000.00 | 14,492,000.00 | 22,913,000.00 | 23,538,000.00 | 28,553,000.00 |
| Total equity | -193.00K | -8.43M | -34.78M | 105.66M | 84.48M | 62.67M | 77.10M |
| Retained earnings | -16.69M | -25.57M | -52.84M | -86.60M | -115.76M | -147.51M | -190.14M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 56.79M | 85.78M | 77.10M | 78.30M | 81.35M | 106.83M |
| Cash & ST investments | 51.64M | 79.70M | 72.21M | 73.13M | 76.42M | 100.64M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 80.93M | 110.95M | 104.69M | 105.65M | 108.77M | 134.25M |
| Total current liabilities | 9.77M | 8.16M | 9.14M | 10.51M | 10.45M | 9.63M |
| Short-term debt | 1.00M | 1.08M | 1.12M | 1.13M | 1.20M | 1.32M |
| Long-term debt | 5.47M | 6.03M | 6.15M | 6.35M | 6.40M | 6.80M |
| Total liabilities | 24,603,000.00 | 24,331,000.00 | 27,110,000.00 | 28,553,000.00 | 39,421,000.00 | 90,195,000.00 |
| Total equity | 56.33M | 86.62M | 77.58M | 77.10M | 69.35M | 44.06M |
| Retained earnings | -156.20M | -166.31M | -178.00M | -190.14M | -213.08M | -258.89M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -6.91M | -7.25M | -11.81M | -23.88M | -17.96M | -19.78M | -26.68M |
| Depreciation & amortization | 66.00K | 86.00K | 776.00K | 979.00K | 1.07M | 1.10M | 1.23M |
| Free cash flow | -8.20M | -11.02M | -14.74M | -24.78M | -24.36M | -22.02M | -32.76M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 5.25M | -- | -- | -- | 0 | 0 | 45.50M |
| Ending cash balance | 1.84M | 16.17M | 23.85M | 6.69M | 12.66M | 13.72M | 12.20M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -95.27 | -30.67 | -43.16 | -61.00 |
| ROA %i | -26.51 | -21.01 | -57.29 | -41.59 | -25.63 | -32.80 | -44.44 |
| ROIC %i | -- | -- | -- | -86.48 | -31.47 | -40.25 | -54.59 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 22.11 | 22.73 | 7.41 | 24.55 | 12.07 | 7.40 | 7.45 |
| Quick ratioi | 21.65 | 22.27 | 7.22 | 24.17 | 11.56 | 6.91 | 6.99 |
| Debt / assetsi | -- | -- | 0.00 | 4.32 | 12.36 | 14.54 | 12.99 |
| LT debt / equityi | -- | -- | -- | 4.28 | 14.46 | 18.39 | 16.34 |
| Interest coveragei | -- | -- | -- | -- | -387.55 | -103.77 | -121.50 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -47.95 | -43.83 | -54.38 | -61.00 | -90.51 | -141.68 |
| ROA %i | -35.40 | -34.01 | -40.90 | -44.44 | -59.96 | -75.51 |
| ROIC %i | -40.42 | -40.64 | -46.19 | -54.59 | -74.68 | -119.74 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.81 | 10.52 | 8.43 | 7.45 | 7.79 | 11.09 |
| Quick ratioi | 5.49 | 10.08 | 8.03 | 6.99 | 7.42 | 10.66 |
| Debt / assetsi | 15.19 | 12.00 | 12.90 | 12.99 | 13.18 | 11.29 |
| LT debt / equityi | 20.05 | 14.12 | 15.96 | 16.34 | 18.95 | 31.41 |
| Interest coveragei | -- | -112.76 | -- | -121.50 | -- | -255.66 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:24:57 · For reference only, not investment advice and not tailored to your situation.